Condition: Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) · Sponsor: Takeda
CIDP is an autoimmune disease. This means that the body's germ fighting (immune) system attacks itself. In CIDP, the immune system attacks the protective covering around the nerves called myelin. Over time, these nerves lose their ability to send signals to the muscles in the body. This leads to muscle weakness and loss of sensation in arms and legs among other symptoms. Participants with CIDP can be treated with a protein called immunoglobulin (or IG). TAK-411 is a special type of immune globulin G (hsIgG) that has been chemically changed. It is made from IG that comes from human plasma. This study will test if TAK-411 can decrease inflammation and improve symptoms of CIDP. The main aim of this study is to check how TAK-411 affects the physical functioning of adults with CIDP when compared with results of the placebo group of a historical trial. Participants may be treated with TAK-411 for up to 1 year (51 weeks) and will be followed up for 3 weeks after last dose. During the study, participants may visit their study clinic up to approximately 21 times.
This description comes directly from the study's public registry record.
Takeda Contact · +1-877-825-3327 · medinfoUS@takeda.com
Always discuss trial participation with your own doctor first.
| University of California San Diego | La Jolla, California, United States | Recruiting |
| California Pacific Medical Center | San Francisco, California, United States | Recruiting |
| UF Health Neurology - Jacksonville | Jacksonville, Florida, United States | Recruiting |
| Visionary Investigators Network | Miami, Florida, United States | Recruiting |
| University of South Florida | Tampa, Florida, United States | Recruiting |
| Emory University | Atlanta, Georgia, United States | Recruiting |
| Beth Israel Deaconess Medical Center | Boston, Massachusetts, United States | Recruiting |
| Mayo Clinic Rochester | Rochester, Minnesota, United States | Recruiting |
| The Curators of the University of Missouri on behalf of University of Missouri Health Care | Columbia, Missouri, United States | Recruiting |
| The Washington University | St Louis, Missouri, United States | Recruiting |
| Penn Blood Disorders Program - Hospital of The University of Pennsylvania | Philadelphia, Pennsylvania, United States | Recruiting |
| Houston Methodist Research Institute | Houston, Texas, United States | Not Yet Recruiting |
+ 8 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06798012